Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod versus fingolimod in pediatric relapsing-remitting multiple sclerosis
2022-501332-42-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Ozanimod arm with Fingolimod arm (2 arms). Primary endpoint: Annualized relapse rate over 2 years. Planned start Feb 2025; status: authorised.
02
Drugs
ozanimodfingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2022-501332-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501332-42-00.